Introduction
============

The global emergence and spread of antimicrobial resistance (AMR) are of great concern to public health. The number of deaths associated with multidrug-resistant (MDR) infections each year has been estimated at more than 25,000 in Europe, 38,000 in Thailand, and 23,000 in the United States ([@B30]; [@B92]; [@B16]). One of the most recent and major threats is the spread of carbapenem-resistant Enterobacteriaceae (CRE), which is becoming a serious healthcare issue in many countries ([@B81]; [@B52]; [@B126]; [@B26]). Previous studies have reported that CRE infections are associated with a higher frequency of sepsis and an increased early mortality rate ([@B124]), particularly in vulnerable populations such as pediatric, elderly, hospitalized, transplant recipient, immunosuppressed, and chronically ill patients ([@B59]; [@B135]). The emergence and spread of *Acinetobacter* species resistant to most of the available antimicrobial agents is also of great concern. *Acinetobacter* infections have high mortality rates; they result in death in up to 65.5% of patients in intensive care unit (ICU) settings ([@B69]). Resistant gram positive bacterial infections have also increased in hospitals and other environments. Methicillin-resistant *Staphylococcus aureus* (MRSA) and vancomycin-resistant Enterococci (VRE) infections are associated with worse clinical outcomes ([@B102]), particularly in immunocompromised patients ([@B91]).

Treatment of MDRO (multidrug-resistant organism) infections presents a major clinical challenge, as the increase in antibiotic resistance leads to a greater risk of therapeutic failure, relapses, longer hospitalizations, and worse clinical outcomes ([@B19]; [@B89]). Moreover, the increase in AMR has outpaced the development of new antibiotics. Currently, there are no validated therapeutic strategies for many MDR infections, and preventing the spread of pathogens through hospital infection control procedures and antimicrobial stewardship programs is often the only tool available to healthcare providers ([@B116]). In this narrative review, we discuss the role of the intestinal microbiota as reservoir of MDRO, and we focus on the use of microbiota transplantation (FMT) for MDR intestinal decolonization, reporting updated literature on its current clinical use.

Gut Microbiota as Reservoir of MDRO
===================================

The human gut microbiota is composed of 10^14^ bacteria organized into microbial communities containing harmless symbionts, commensal bacteria, and opportunistic pathogens, all of which play crucial roles in human health and disease ([@B103]). The gut bacterial community is dominated by Firmicutes and Bacteroidetes in healthy adults, which account for 90% of the total gut bacteria. Small percentages of Actinobacteria, Proteobacteria, and Verrucomicrobia are also present ([@B93]). Although the microbiota profile of each person is unique, a conserved set of gut bacteria, the *core* microbiota, is shared amongst most individuals. This suggests that the *core* microbiota plays a role in maintaining health ([@B93]). The microbial *core* aids in several important functions, including digestion of polysaccharides, development of the immune system, biosynthesis of vitamins, and defense against infections ([@B93]; [@B103]; [@B21]; [@B34]; [@B72]). In physiological conditions, the gut microbiota is stable (i.e., eubiotic status), but when perturbative events occur (e.g., dietary changes, stress, antibiotic administration, different hygienic conditions), the equilibrium amongst the bacteria and between the bacteria and the host breaks (i.e., dysbiotic status). This results in adverse health effects and loss of protection against pathogen colonization ([@B112]).

The gut is also a large reservoir of opportunistic pathogens. This is particularly relevant for hospitalized patients, especially when antibiotic-based therapies are used that may select MDR bacteria already present in their gut microbiota ([@B95]; [@B9]). These opportunistic pathogens may translocate across the intestinal barrier or, after fecal contamination of skin and other body sites, cause infections, especially in catheters or intravenous lines ([@B129]).

The large reservoir of antibiotic-resistance genes that is present in the gut is called the "*resistome*" ([@B15]). The gut reservoir includes two different *resistomes*: the resident *resistome*, which is carried by the commensal bacteria, and the transitory *resistome*, which is carried by bacteria that are only periodically present in the gut. The latter bacteria can transfer their resistance to the commensal microbiota or become permanent microbiota residents themselves ([@B5]). Consequently, there is considerable interest in characterizing the antibiotic resistance gene reservoir of the human gut microbiota and to understand to what extent the antibiotic resistance genes can spread among different members of the gut microbiota, particularly between commensals and opportunistic pathogens ([@B87]).

From Colonization to Antimicrobial Resistance Through Microbiota-Mediated Mechanisms
------------------------------------------------------------------------------------

The exact mechanism by which specific components of the microbiota influence colonization by other pathogens is not yet fully known. Previous studies have found that particular commensal species inhibit the growth of specific MDR bacteria. This has been shown in mice, where VRE did not colonize microbiota containing the obligate anaerobe *Barnesiella* spp. ([@B125]; [@B75]). [@B12] also demonstrated that administration of a defined bacterial consortium containing *Blautia producta* and *Clostridium bolteae* prevented colonization of VRE and cleared persistent VRE in mice. In humans, one study reported that four species of bacteria *Desulfovibrio, Oscillospira, Parabacteroides*, and *Coprococcus*, where not present in the microbiota of adult patients colonized by extended-spectrum β-lactamase (ESBL)-producing bacteria, whereas these four species were present in the microbiomes of patients not colonized by ESBL-producing bacteria ([@B42]).

Little knowledge is available regarding the mechanisms which promote progression from colonization to infection. [@B78] and [@B41] reported that GI carriage of *Klebsiella pneumoniae* (KP) in hospitalized patients was associated with a greater risk of developing an infection ([@B78]; [@B41]). Additionally, gut colonization by MDR bacteria has been described as an important risk factor for severity outcomes in both solid organ and hematopoietic stem cell transplantation (HSCT) ([@B86]; [@B88]; [@B73]).

Present Strategies for Fighting Antimicrobial Resistance
========================================================

Control Measures and Decolonization Regimes
-------------------------------------------

Currently, several strategies have been adopted to fight AMR ([Figure 1](#F1){ref-type="fig"}). In particular, the increase in healthcare-acquired infections has led to a focus on improving control measures and infection prevention. A core component of this strategy is active surveillance for early identification of MDR carriers. MDR transmission usually occurs through person-to-person contact with healthcare providers and through contamination of the hospital environment, especially for pathogens such as Enterobacteriaceae and *Acinetobacter baumanii*. Depending on the local epidemiology, screening is usually performed for CRE, carbapenem-resistant (CR) *Pseudomonas aeruginosa*, VRE, and MRSA through rectal and nasal swabs. Early detection tests are usually performed on patients with risk factors for carrying MDR bacteria, including contact with colonized or infected patients, arrival from high incidence regions, and admission to high acuity wards (e.g., ICU, transplant units, onco-hematology units) ([@B33]). When MDR carriers are identified, hospitals may have various policies for preventing infections and spreading of colonization, including contact precautions (antiseptic hand hygiene, use of gloves, gowns, single rooms or cohort, and dedicated patient equipment); decolonization of MRSA nasal carriers with mupirocin topic application; intensification of environmental cleaning and disinfection; and education of healthcare providers, patients, and visitors ([@B18]). Decolonization of the intestinal tract through bowel preparations or antibiotic treatment has undoubtedly attracted great interest over the past few years. However, most of the available literature on this topic confirms the limited efficacy of using non-absorbable or systemic antibiotics to eradicate MDR bacteria from the intestinal tract ([@B96]; [@B6]). One of the major limits is the limited time of MDR bacterial clearance after the decolonization procedure ([@B49]; [@B62]). Moreover, it has been observed that decolonization strategies using non-absorbable antibiotics have marked effects on the bacterial population, with resistance increasing during treatment. A considerable "rebound effect" of select antibiotic-resistant organisms in the intestinal tract has been observed after discontinuation of the decolonization regimens ([@B84]). The latest ESCMID-EUCIC^[1](#fn01){ref-type="fn"}^ clinical guidelines on decolonization of multidrug-resistant Gram negative bacteria carriers ([@B117]) did not recommend routine decolonization of third-generation cephalosporin-resistant Enterobacteriaceae and CRE carriers and did not find sufficient evidence to provide recommendations for or against any intervention in patients colonized with aminoglycoside-resistant Enterobacteriaceae, colistin-resistant Gram negative organisms, carbapenem-resistant *Acinetobacter baumanii*, cotrimoxazole-resistant *Stenotrophomonas maltophilia*, fluoroquinolone-resistant Enterobacteriaceae, pan-drug-resistant Gram negative organisms, or extremely drug-resistant *Pseudomonas aeruginosa*. Overall, decolonization using antimicrobials is not currently recommended. Conversely, inappropriate use may be responsible for increased dysbiosis and further increases in antibiotic resistance rates ([@B45]).
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Antimicrobial and Diagnostic Stewardship Programs
-------------------------------------------------

Antibiotic prescribing policies and implementation of Antimicrobial Stewardship Programs have also played a crucial role in preventing MDR spread and infections. Depending on local infection control committee policies and funding availability, Antimicrobial Stewardship Programs may include a multidisciplinary team, antibiotic prescription guidelines, review of antibiotic appropriateness prescriptions, de-escalation therapy, formulary restriction and pre-authorization requirements, audit of antibiotic use, and monitoring antibiotic consumption with indicators ([@B104]). Antimicrobial stewardship programs are of particular importance, because it is well-known that misuse and overuse of antibiotics accelerate the development of resistance. Therefore, it is necessary to limit the reckless use of antibiotics, especially the newest ones. In the last 40 years, the discovery of new molecules has been limited ([@B141]). Recently, new promising antibiotics have been developed, finally reversing the declining trend of antimicrobial development ([@B118]). However, resistance to all antibiotics will develop eventually. Hence, the discovery of new antimicrobials, although important, does not seem to be the definitive solution to AMR.

Diagnostic stewardship also plays a crucial role in controlling AMR. Current hospital protocols use culture-based screening as first step for identifying MDR carriers by Matrix Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS), and secondly by sequencing AMR genes for early pre-emptive antimicrobial therapy based on predicted susceptibility ([@B97]). As technology in microbiologic diagnostics advances, and as outbreaks of MDR infections put 1000s of lives at risk, *ad hoc* outbreak-specific diagnostics need to be implemented ([@B139]; [@B38]). We expect future AMR policies to include microbiome profiling, such as metataxonomic analysis of MDR-related microbiota and use of whole genome sequencing to type MDR strains ([Figure 2](#F2){ref-type="fig"}). These microbiome-based approaches may not only contribute to a better knowledge of MDR pathogens, but also give an additional tool to clinical management of infections.
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Conveying the Present to the Future for Fighting Against Antimicrobial Resistance
=================================================================================

New solutions are urgently required to reduce the prevalence of MDRO and to control colonization. In this section, we discuss FMT as an advanced approach for combating AMR ([Figure 3](#F3){ref-type="fig"}) and other strategies (i.e., probiotics and bacteriophages) as potential alternative antimicrobial stewardship solutions.
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FMT: Present Use in Clinical Practice in Adult and Pediatric Populations
------------------------------------------------------------------------

In current clinical practice, FMT is being used as a therapeutic option for recurrent infection with toxin-producing *Clostridium difficile* (rCDI) in adults ([@B127]; [@B14], [@B13]). As per the latest guidelines of Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA)^[2](#fn02){ref-type="fn"},[3](#fn03){ref-type="fn"}^, FMT is recommended for patients with multiple recurrences of CDI when the appropriate antibiotic treatments have failed (strong recommendation, moderate quality of evidence) ([@B79]). Use of FMT is also under study for the treatment of primary CDI ([@B57]). Randomized controlled trials (RCTs), systematic reviews, and meta-analyses have been performed to confirm the effectiveness of FMT, which is reported to be between 77 and 94% with administration via the proximal small bowel, and around 80--100% with instillation in the colon ([@B79]). Oral capsules with lyophilized fecal microbiota product have also been found to be equally effective to frozen product given by colonoscopy ([@B61]) or enema ([@B55]).

The safety of FMT has also been established ([@B63]; [@B51]), although episodes of bacteremia following FMT have been reported ([@B8]; [@B133]; [@B106]). In pediatric patients, an increase in the prevalence of CDI has also been observed over the past decade ([@B101]; [@B138]), especially in children given prolonged antibiotic therapy or those who have chronic inflammatory bowel diseases (IBDs), oncological conditions, and who have had recent surgery ([@B64]; [@B48]). An overall increase in recurrences of CDI has also been reported, estimated at around 20--30% ([@B82]). According to the latest joint position paper on FMT for rCDI in children released by the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and by the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) in January 2019, 336 FMTs for rCDI have been performed in the pediatric population in the United States alone, with a success rate of 81% after a single delivery and nearly 90% when patients received a second FMT ([@B22]). This is consistent with previous reports demonstrating its effectiveness (between 90 and 100%) and safety ([@B47]). In general, FMT-related adverse events in pediatric patients were infrequent ([@B17]), mainly characterized as minor and transient adverse events of the GI tract. No bacterial translocation or sepsis were reported. Current data suggest that the age of the recipient does not affect efficacy or safety, although definitive data from pediatric RCTs are not yet available. The youngest reported recipient so far was a 0.5-year-old infant ([@B132]), and FMT in other patients less than 2-years-old has also been reported ([@B58]; [@B98]; [@B131]; [@B65]).

In addition to its use for MDR infections, FMT has also been described as a promising therapy for other disorders associated with the alteration of intestinal microbiota, including intestinal inflammatory diseases such as IBD ([@B132]; [@B85]). Several RCTs, case series, and case reports on FMT in IBD have been published. Clinical remission is seen in 28.8% of patients and a clinical response is seen in 53% during follow-up, according to a recent systematic review and meta-analysis of 459 IBD patients ([@B32]). In pediatrics, several case series on FMT for IBDs have also been published ([@B24]; [@B4]); [@B32] reported a total of 67 pediatric patients, which will need to be updated with the rising use of FMT in this field. The currently published data show a clinical response rate ranging between 56 and 100% ([@B66]; [@B132]; [@B43]). This wide variability may be due to the different locations of disease in Crohn's disease and ulcerative colitis, as well as the different routes of FMT administration used in the published studies ([@B47]; [@B132]; [@B4]). Side effects in both populations have been confirmed to be modest and transient, involving the GI tract ([@B47]; [@B132]). To the best of our knowledge, the youngest reported patient that underwent FMT for very early-onset IBD was 2 years and 3 months old ([@B142]).

Extensive studies on the microbiome and eventually FMT as a therapeutic strategy have been performed for other diseases, including metabolic diseases ([@B44]; [@B144]), diabetes mellitus ([@B128]), obesity and non-alcoholic liver disease ([@B1]; [@B23]; [@B77]; [@B94]; [@B119]; [@B83]), HIV ([@B130]; [@B105]), and autism spectrum disorders ([@B60]), with initial but promising results in terms of microbiota profiling and clinical outcomes. The use of FMT in the fields of hematology and oncology, specifically HSCT, has also gained interest. The gut microbiota plays a pivotal role in intestinal inflammation and the immune response ([@B143]; [@B2]). Indeed, disruption of the host microbiota following prolonged antimicrobial therapy contributes to the pathogenesis of graft-versus-host-disease (GVHD) ([@B54]; [@B46]; [@B107]), and is an independent predictor of poor outcome ([@B136]) and overall mortality in allo-HSCT recipients ([@B122]). Although the initial reports are encouraging ([@B121]; [@B25]), RCTs are still ongoing and the results are pending. Depending on these results, FMT may become a useful tool for preventing HSCT-related morbidity and mortality.

FMT: Present Use for Decolonization of MDRO
-------------------------------------------

Based on current clinical practice, and considering the increased threat of AMR, FMT has been considered for the eradication of drug-resistant bacteria from the intestinal reservoir. Studies show that adult patients undergoing prolonged antibiotic therapy for chronic infections, such as rCDI, have a greater amount of antibiotic resistance genes in their intestinal microbiota compared to healthy adults ([@B56]; [@B80]). Moreover, the number and diversity of antibiotic resistance genes decreased after FMT, especially if repeated FMTs were performed ([@B56]; [@B80]). However, AMR genes can also be acquired from FMT donor stool, hence healthy stool donor selection is fundamental and needs further standardization ([@B70]).

Since 2014, case reports and case series have described the use of FMT for MDR intestinal decolonization ([@B40]). Given the rising interest in this new approach, retrospective and prospective single-center and multi-center studies have been successively performed ([Table 1](#T1){ref-type="table"}). Currently, there are several RCTs evaluating the efficacy of FMT in patients colonized by MDR bacteria (NCT03802461; NCT03786900; NCT03643887; NCT03527056; NCT03391674; NCT03367910; NCT03167398; NCT03063437; NCT03029078; NCT02922816; NCT02906774; NCT02816437; NCT02543866; NCT02472600; NCT02461199; NCT02390622; and NCT02312986^[4](#fn04){ref-type="fn"}^). To date, only one RCT is complete ([@B50]), which showed a slight decrease of ESBL/CRE carriage compared to controls when using non-absorbable antibiotics followed by FMT. However, the unfavorable results are potentially due to the study design and early trial termination. From the analysis of the literature available so far ([Table 1](#T1){ref-type="table"}), 142 patients undergoing FMT for MDR intestinal decolonization globally have been described in 23 total reports, with a mean recipient age of 54.8 years (range: 14--89 years). The most commonly isolated pre-FMT MDR intestinal bacteria were CRE and VRE; MDR organisms in other sites, including *Pseudomonas aeruginosa*, MRSA, and *Acinetobacter* were also reported. The most commonly used route of administration was *via* naso-duodenal tube (45/142, 31.6%), followed by naso-gastric tube (36/142, 25.3%), oral capsules (24/142, 16.8%), enema (23/142, 16.1%), colonoscopy (4/142, 2.7%), and through pre-existing stomies (2/142, 1.3%). In 9/142 (6.2%) patients, the route of administration was not specified. Microbiological clearance of MDR bacteria on fecal samples or rectal swabs was achieved on 77.5% of patients. Microbiological follow-up was on average 180.8 days (range: 14--750 days). Donors were chosen among family members of recipients in 19/142 (13.4%) of cases, while most studies used samples from healthy unrelated donors (83/142, 58.5%). The donor was not specified in 21/142 (14.8%) of cases. An experimental drug was used in two studies on 19 patients \[RBX2660 ([@B28]); SER-109 ([@B71])\]. Age of donors, where specified, ranged from 6 to 60 years. Preparation of patients for FMT, where reported, included fasting for at least 12 h (21.2%), introduction of treatment with a proton pump inhibitor (PPI) twice daily to neutralize gastric acid (49.3%), discontinuation of antibiotic treatment (55.5%), and bowel lavage with laxative drugs (50%). Administration of oral antibiotics was part of the preparation in one case report ([@B67]), in the only RCT completed to date ([@B50]), and in a recent retrospective case-control study ([@B99]). Notably, [@B99] reported a unique preparation protocol that included a 3-day nasopharyngeal decolonization with 0.12% chlorhexidine gluconate 8 days before FMT, two bowel lavages (5 days before FMT and the day before the procedure), 5 days of antimicrobial treatment prior to FMT with an oral non-absorbable bi-antibiotic (mostly colistin and aminoglycoside, replaced by sulfadiazine or fusidic acid in case of resistance), post-FMT environmental decontamination, room transfer, and removal of medical tubes and catheters in order to limit post-FMT recolonization ([@B99]). In the published studies, stool suspension for transplant was prepared using fresh stools for 30 patients (21.1%), frozen samples for 27 patients (19.0%), oral capsules of fecal preparation for 16 patients (11.3%), was not specified in 35.2% of cases, and an experimental drug was used in 19 cases (13.4%). One serious adverse event was reported: in the only completed RCT, a 57-year-old female patient with known liver cirrhosis and recurrent episodes of hepatic encephalopathy was hospitalized 2 weeks after FMT for an episode of encephalopathy. This event was classified as a possible "Suspected Unexpected Serious Adverse Reaction" ([@B50]). In the other reports, the adverse events described were minor, transient, and involved the gastro-intestinal tract (loose stools/mild diarrhea, transient mild abdominal discomforts or cramps, food intolerance, constipation).

###### 

List of case reports and studies describing FMT for MDR intestinal decolonization.

  Authors   Study design                                N. of pts   Age (mean)   Co-morbidities                                                                                 CRE                               VRE                 ESBL                                Other bacteria   Route FMT                                                                                                                            Donor                            Outcome                                       Clearance %                                                                                                                                              Follow up (days, mean)   AE    
  --------- ------------------------------------------- ----------- ------------ ---------------------------------------------------------------------------------------------- --------------------------------- ------------------- ----------------------------------- ---------------- ------------------------------------------------------------------------------------------------------------------------------------ -------------------------------- --------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------ ----- --------------------------------------------------------------------------------------
  [@B7]     Retro-spective single center                10          48           Hematologic malignancy                                                                         1 EC, 2 CF, 1 KP                  ns                  X                                   X                4 CR PA                                                                                                                              8 enema, 2 NGT                   8 FM 2 HUD                                    Major decolonization 7/10, persistent decolonization 6/10                                                                                                70%                      475   Constipation, grade I diarrhea.
  [@B9]     Case report                                 1           51           Multiple myeloma, IC                                                                           KP                                NDM                                                     X                                                                                                                                                     NDT                              HUD                                           Negative rectal swabs cultures, persistence of *bla*NDM. No infections, reduced constipation, improved mood.                                             100                      26    Mild and transient GI symptoms
  [@B10]    Prospective single center                   20          51           Blood disorders                                                                                KP                                NDM-1               X                                   X                CR PA, MDR *Acinetobacter* (respiratory tract and wound)                                                                             NDT                              HUD                                           15/20 decolonized after 1 month and 13/14 after 6 months                                                                                                 75                       187   Mild and transient AE or pre-existing conditions
  [@B20]    Case report                                 1           66           Quadriplegia, large sacral wound, recurrent MDRO sepsis and UTIs                               X                                 ns                  X                                                    MRSA (respiratory tract, urine, abdominal fluid), CR PA (respiratory tract), MDR *Acinetobacter* (respiratory tract and wound), CD   Colon                            FM                                            Resolution of CDI. Marked reduction in MDRO colonization and infections                                                                                  100                      730   None
  [@B27]    Prospective multi center                    17          73           Renal, hepatic diseases                                                                        6 KP,1KP+EC, 1 EC                 7 OXA-48, 1 NDM-1   7 Van A, 1 Van B, 1 Van A + Van B                                                                                                                                                         NGT                              HUD                                           Clearance CRE 3/8, Clearance VRE 7/8                                                                                                                     CRE 37.5, VRE 87.5       90    None
  [@B28]    Prospective single center                   11          75           rCDI                                                                                                                                                 X                                                                                                                                                                                         Enema                            Microbiota based drug (RBX2660)               8/11 decolonized                                                                                                                                         72.7                     180   ns
  [@B31]    Prospective multi center                    9           ns           ns                                                                                                                                                   Van A                                                                                                                                                                                     ns                               ns                                            Clearance 9/9                                                                                                                                            100                      42    ns
  [@B37]    Case report                                 1           14           HLH, recurrent severe KPC arthritis                                                            KP                                KPC                                                                                                                                                                                                           NDT                              FM                                            KPC clearance; no recurrence of clinical infection                                                                                                       100                      240   ns
  [@B39]    Case report                                 1           84           rCDI                                                                                           KO                                VIM-1                                                                    CD                                                                                                                                   Colon                            FM                                            CRE clearance CD positive at 6 weeks follow-up, negative at 6 months follow-up.                                                                          100                      180   Food intollerance, constipation
  [@B50]    RCT                                         22          ns           ESBL carriers ≥ 1 sympto-matic infection requiring systemic antibiotics within 180 days        9 EC, 2 KP, 1 *E. cloacae*,1 CF   7 OXA, 5 NDM                                            X                                                                                                                                                     NGT/ oral capsules               HUD + donor stool bank                        Clearance ESBL/CRE in 9/22                                                                                                                               41                       48    4 SAE, 1 possibly related (hepatic encephalo-pathy in pt with known liver cirrhosis)
  [@B53]    Case report                                 1           33           CDI                                                                                                                                                  X                                                    CD                                                                                                                                   Enema (FMT \#1), NDT (FMT \#2)   FM                                            Failure of VRE clearance, clearance of CDI                                                                                                               0                        90    None
  [@B68]    Case series                                 1           31           Recurrent ESBL pyelo-nephritis                                                                                                                                                           X                                                                                                                                                     Colon                            ns                                            Clearance of ESBL                                                                                                                                        100                      42    None
  [@B67]    Case report                                 1           82           ns (long term facility resident)                                                               KP                                OXA-48                                                                                                                                                                                                        NDT                              HUD                                           Clearance of KP OXA-48                                                                                                                                   100                      14    None
  [@B71]    Prospective single center study             8           ns           rCDI                                                                                                                                                 X                                                                                                                                                                                         Oral capsules                    Microbiota based biological agent (SER-109)   8/8 VRE titers reduced below the limit of detection                                                                                                      100                      28    ns
  [@B90]    Case report                                 1           66           rCDI non-responsive to standard treatment                                                      X                                 ns                                                                       CD                                                                                                                                   NDT                              ns                                            Clearance of CRE and CD                                                                                                                                  100                      100   ns
  [@B99]    Retro-spective Single center Case-control   10          59           Renal, hepatic diseases                                                                        X                                 ns                                                                       *Acinetobacter*                                                                                                                      NGT                              ns                                            Clearance of CRE/*Acinetobacter* in 8/10 pts and 8/15 procedures                                                                                         53                       180   ns
  [@B109]   Case report                                 1           60           chronic kidney rejection, recurrent ESBL pyelo-nephritis                                                                                                                                 X                                                                                                                                                     NDT                              HUD                                           Negative rectal swabs. No recurrence of IVU at 12 weeks clinical follow-up                                                                               100                      84    Mild GI symptoms
  [@B108]   Prospective single center                   15          51           Recurrent UTIs, renal transplant, ESRD                                                                                                                                                   X                                                                                                                                                     NDT                              HUD                                           3/15 decolonization after 1 FMT, 3/7 after 2 FMT                                                                                                         40                       28    ns
  [@B111]   Case series                                 3           74           CDI and htn; CDI, pyogenic spondylitis, HTN and DM; septic arthritis in rheumatoid arthritis                                                         Van A                                                CD                                                                                                                                   Enema                            FM                                            Pt 1 e 2 resolution of CDI; all 3 pts persistence of VRE carriage (case 1: 12 weeks follow-up; case 2: 10 weeks follow-up; case 3: 21 weeks follow-up)   0                        100   None
  [@B113]   Case report                                 1           34           DM, chronic kidney failure, recurrent Pseudo-monas MDR UTIs                                                                                                                              X                CR PA                                                                                                                                NDT                              HUD                                           PA clearance, EC ESBL persistence. No recurrence of PA IVU for 18 months, 1 ESBL IVU 8 months after FMT                                                  50                       90    None
  [@B114]   Case report                                 1           33           Heart transplant, recurrent MDRO infections, CDI                                                                                                     X                                                    CD                                                                                                                                   NGT                              FM                                            No CDI symptoms. Reduction in VRE fecal dominance.                                                                                                       100                      365   None
  [@B134]   Prospective single center                   1           83           Recurrent UTIs and inconti-nency                                                               KO KP                             ns                                                                       CD                                                                                                                                   Colon                            HUD                                           Resolution of symptoms, no recurrences                                                                                                                   100                      750   None
  [@B137]   Prospective single center                   5           28           Nosocomial MRSA enterocolitis                                                                                                                                                                             MRSA                                                                                                                                 3 NDT/ 2 stomies                 2 HUD 3 FM                                    MRSA clearance, 100% enterocolitis cure rate                                                                                                             100                      90    None
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To the best of our knowledge, only two pediatric cases of FMT for MDR intestinal decolonization have been described so far. The first pediatric case report ([@B37]) describes a 14-year-old patient undergoing immunosuppressive treatment for hemophagocytic lymphohistiocytosis, affected by recurrent infections with highly resistant carbapenemase-producing *K. pneumoniae*. Despite prolonged antibiotic therapy, the patient's stool samples remained persistently colonized, putting her at risk for further infective relapses. The patient underwent FMT *via* naso-duodenal tube, with microbiological clearance at an 8-month follow-up, and clinical absence of infections 1.5 years after FMT. The second patient ([@B7]) has been described in a recent retrospective study among adult hematologic patients. The patient was a 16-year old female with acute myeloid leukemia (AML) that underwent two FMTs for VRE and ESBL-producing bacteria 98 days after HSCT, resulting in decolonization of VRE and persistence of ESBL-producing bacteria, with no reported adverse events.

As reported herein, great variability in terms of the mode of delivery of emulsion, sample preparation, donor selection, and targeted MDRO are seen for MDRO decolonization via FMT. This reflects the lack of knowledge regarding the effects of each variable on the efficacy of FMT. Therefore, further studies and RCTs are needed to determine a standardized methodology and best clinical practice.

Other Possible Strategies for Decolonization of MDR Bacteria
------------------------------------------------------------

A potential microbial strategy that needs to be considered in the prevention and treatment of MDR is the use of probiotics, which have antimicrobial activity against pathogens. Many studies have been conducted with this purpose and have produced interesting results, especially regarding Gram positive organisms. In fact, clinical trials on intestinal VRE decolonization showed marked efficacy of probiotics in eradicating VRE carriage ([@B76]; [@B115]). Similarly, in a recent clinical trial, MRSA colonization of the GI tract was reduced by daily administration of oral *Lactobacillus rhamnosus*, although colonization was not reduced in other body sites ([@B29]). However, results from studies using probiotics for Gram negative decolonization are not promising. To date, two randomized double-blind placebo-controlled clinical trials showed that probiotics were not effective in decolonizing hospitalized patients or long-term residents harboring MDR Gram negative bacilli ([@B120]; [@B100]). Ongoing RCTs, such as NCT036449966 on probiotics and MDR urinary tract infections, will definitely give notable contributions to the field. Lactobacilli, Lactococci, and Bifidobacteria are classified as "generally regarded as safe" ([@B36]; [@B110]). However, it has also been reported that RCTs using probiotics, prebiotics, and symbiotics often lack adequate reporting of adverse effects ([@B3]). Although substantial challenges regarding the safety, mechanisms of action, and real-life indications of probiotic use need to be fully addressed, the therapeutic potential of probiotics in reducing and preventing MDR bacterial colonization is promising. RCTs and comprehensive studies are certainly needed to expand this field and to evaluate the potential efficacy of probiotics for the treatment and prevention of MDR infections.

Another potential tool for combating AMR could exploit the use of bacteriophages directed against specific bacterial strains ([@B140]). Phage therapy could have major advantages over antibiotics, such as host-specificity and consequent low toxicity in humans ([@B11]). Additionally, its efficacy against biofilms could make phage therapy suitable for the treatment of biofilm-associated infections, such as MRSA ([@B123]) and *P. aeruginosa* infections ([@B35]). The safety of all the phage therapy products currently under study is generally excellent. Nevertheless, phage therapy and enzymes can both induce rapid endotoxin release due to rapid cell lysis, as much as bactericidal antibiotics ([@B74]). Therefore, there are currently no phage therapy products approved for human use in the EU or United States.

Conclusion
==========

Antimicrobial resistance is increasing worldwide and is causing a rise in hospital-acquired infections, deaths, and costs. Microbiota-based strategies need to be considered in the prevention and treatment of MDRO. In particular, FMT is a promising tool, especially in cases where conventional therapies have not proven effective. So far, FMT has been shown to be effective and safe. However, RCTs are needed to standardize the methodology and set regulatory boundaries in order to include FMT in MDR clinical management.
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